Scholarlink

<p>Human epidermal growth factor receptor&#xa0;2 (HER2) overexpression or amplification of the human <i>ERBB2</i> oncogene occurs in approximately one-fifth of breast cancers and, of these, two-thirds are hormone receptor (HR)-positive (HR+). The introduction of HER2-targeted therapies in recent years has significantly improved survival outcomes in patients with this tumor subtype. However, disease recurrence risk is 10–30% at 5&#xa0;years with a different pattern between patients with HER2+/HR+ and HER2+/HR-negative (HR−) early breast cancer, with HR+ patients having a lower risk than those with HR− disease in the first 5&#xa0;years, but a slightly higher risk at 5–10&#xa0;years post-surgery. This highlights a crucial need to explore the underlying mechanisms for these differences to address specific treatment needs and to optimize systemic adjuvant treatment outcomes. Therefore, this narrative review provides an overview of published data regarding the recognized factors and ongoing challenges associated with the risk of relapse in women with HER2+ early breast cancer and proposes potential adjuvant treatment strategies to minimize risk of recurrence in high-risk patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月8日

查看全文
  • Marina E. Cazzaniga,
  • Luis Costa,
  • Gilles Freyer,
  • Joseph Gligorov,
  • Henrik Lindman,
  • Piotr J. Wysocki,
  • Rupert Bartsch

摘要

Human epidermal growth factor receptor 2 (HER2) overexpression or amplification of the human ERBB2 oncogene occurs in approximately one-fifth of breast cancers and, of these, two-thirds are hormone receptor (HR)-positive (HR+). The introduction of HER2-targeted therapies in recent years has significantly improved survival outcomes in patients with this tumor subtype. However, disease recurrence risk is 10–30% at 5 years with a different pattern between patients with HER2+/HR+ and HER2+/HR-negative (HR−) early breast cancer, with HR+ patients having a lower risk than those with HR− disease in the first 5 years, but a slightly higher risk at 5–10 years post-surgery. This highlights a crucial need to explore the underlying mechanisms for these differences to address specific treatment needs and to optimize systemic adjuvant treatment outcomes. Therefore, this narrative review provides an overview of published data regarding the recognized factors and ongoing challenges associated with the risk of relapse in women with HER2+ early breast cancer and proposes potential adjuvant treatment strategies to minimize risk of recurrence in high-risk patients.